Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next

Young, Michael D.; Cripps, Allan W.

doi:10.4161/hv.25311

Cited by 12 publications

(7 citation statements)

References 40 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccination of pregnant women against group B streptococci 27 and respiratory syncytial virus (RSV) 28 has not yet been shown to be effective at preventing neonatal or infant infection, but it has the potential to reduce the burden of disease in the youngest infants. Other examples include the use of specific neutralizing antibodies purified from immune donors to prevent the transmission of various viruses, including varicella zoster virus, HBV and measles virus 29 . Individuals with inherited antibody deficiency are without defence against serious viral and bacterial infections, but regular administration of serum antibodies from an immunocompetent donor can provide almost entirely normal immune protection for the antibody-deficient individual.…”

Section: Vaccines Induce Antibodiesmentioning

confidence: 99%

A guide to vaccinology: from basic principles to new developments

2020

View full text Add to dashboard Cite

Immunization is a cornerstone of public health policy and is demonstrably highly cost-effective when used to protect child health. Although it could be argued that immunology has not thus far contributed much to vaccine development, in that most of the vaccines we use today were developed and tested empirically, it is clear that there are major challenges ahead to develop new vaccines for difficult-to-target pathogens, for which we urgently need a better understanding of protective immunity. Moreover, recognition of the huge potential and challenges for vaccines to control disease outbreaks and protect the older population, together with the availability of an array of new technologies, make it the perfect time for immunologists to be involved in designing the next generation of powerful immunogens. This Review provides an introductory overview of vaccines, immunization and related issues and thereby aims to inform a broad scientific audience about the underlying immunological concepts.

show abstract

Section: Vaccines Induce Antibodiesmentioning

confidence: 99%

A guide to vaccinology: from basic principles to new developments

2020

View full text Add to dashboard Cite

show abstract

“…In contrast to the guidelines for hepatitis A, those for rubella have not altered since 2013 or earlier. 29,30 Each of the guidelines examined recommends vaccination with a rubellacontaining vaccine (MMR) for susceptible individuals exposed to rubella in the absence of contraindications. 6,11,18,19,31,32 The rationale provided is that while unlikely to prevent infection from current exposure, vaccination will prevent infection in the instance of future exposures.…”

Section: Rubellamentioning

confidence: 99%

The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles

Young

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Derived from pooled blood donations, polyvalent immunoglobulins are used for post-exposure prophylaxis as one aspect of the public health management of hepatitis A, rubella and measles. This review summarizes the safety profile of these blood products and the current recommendations for their use for the prevention of hepatitis A, rubella and measles among people who have been exposed to these diseases. The current recommendations are drawn from the most recent publicly available national guidelines of the United States,

show abstract

“…13 Passive immunization or immunoprophylaxis is the administration of an antibody to prevent infection. 14 In the context of RSV prevention, an RSV-neutralizing mAb can be administered for each infant before the start of the respective RSV season or at birth for those infants born during the RSV season. Currently, palivizumab (Synagis; MedImmune, Gaithersburg, Maryland) is the only mAb approved for RSV immunoprophylaxis.…”

mentioning

confidence: 99%

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Aliprantis

Wolford

Caro

et al. 2020

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infection and related morbidity and mortality in infants. Passive immunization with an RSV-neutralizing antibody can provide rapid protection to this vulnerable population. Proof-of-concept for this approach has been demonstrated by palivizumab; however, the use of this antibody is generally restricted to the highest-risk infants due to monthly dosing requirements and its cost.To address the large unmet medical need for most infants, we are evaluating MK-1654, a fully human RSV-neutralizing antibody with half-life extending mutations targeting site IV of the fusion protein. In this 2-part, placebo-controlled, double-blind, first-inhuman study, 152 healthy adults were randomized 3:1 to receive a single dose of MK-1654 or placebo in 5 cohorts (100 or 300 mg as an intramuscular dose or 300, 1000, or 3000 mg as an intravenous dose). Safety, pharmacokinetics, antidrug antibodies, and RSV serum-neutralizing antibody titers were evaluated through 1 year. MK-1654 serum concentrations increased proportionally with dose and resulted in corresponding elevations in RSV serum-neutralizing antibody titers. The antibody displayed a half-life of 73 to 88 days and an estimated bioavailability of 69% at the 300-mg dose. The overall safety profile of MK-1654 was similar to placebo, and treatment-emergent antidrug antibodies were low (2.6%) with no associated adverse events. These data support the continued development of MK-1654 for the prevention of RSV disease in infants.

show abstract

Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next

Cited by 12 publications

References 40 publications

A guide to vaccinology: from basic principles to new developments

A guide to vaccinology: from basic principles to new developments

The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Contact Info

Product

Resources

About